CNBCBiogen Alzheimer’s drug and the battle over dementia treatment of the futureJun 12, 2021Willem MarxBy Willem Marxmore_vert
Harvard HealthA new Alzheimer's drug has been approved. But should you take it?Jun 7, 2021Andrew BudsonBy Andrew Budsonmore_vert
POLITICOControversial drug approval stokes concern about lack of a permanent FDA chiefJun 11, 2021Sarah Owermohle, Lauren Gardner & Adam CancrynBy Sarah Owermohle, Lauren Gardner & Adam Cancrynmore_vert
Financial TimesThe Alzheimer's economy: is the new $56,000-a-year drug worth it?Jun 11, 2021Sarah Neville, Hannah Kuchler & Nikou AsgariBy Sarah Neville, Hannah Kuchler & Nikou Asgarimore_vert
BioSpaceFallout Continues as Third FDA Panel Member Resigns Over Aduhelm ApprovalJun 11, 2021more_vert
The AtlanticThe Drug That Could Break American Health CareJun 11, 2021Rachel E Sachs & Nicholas BagleyBy Rachel E Sachs & Nicholas Bagleymore_vert
FiercePharmaBiogen's $56K price on Aduhelm 'simply unacceptable,' Alzheimer's Association says after vouching for FDA approvalJun 14, 2021Noah Higgins-DunnBy Noah Higgins-Dunnmore_vert
NPR3 Experts Quit An FDA Panel Over Alzheimer's Drug ApprovalJun 11, 2021Bill ChappellBy Bill Chappellmore_vert